emerging glp-1 gip weight loss treatments 2025 Therapy Part 1: Setting Realistic Expectations – Sarah Hormachea What is the pipeline for

Gydesen S, Andreassen KV, Hjuler ST, Christensen JM, Karsdal MA, Henriksen K

Theyre unafraid to reformulate, repackage, and re-align based on what their target customers have to say

Resistance training, may increase your resting metabolic rate

Building on the therapeutic success of GLP-1RAs, recent pharmacological developments have introduced GLP-1 with glucose-dependent insulinotropic polypeptide (GIP)/glucagon (GCG) dual or triple receptor agonists simultaneously target multiple incretin pathways, offering a novel multi-targeted approach to MASLD treatment

This study population was divided into two cohorts: (1) Semaglutide cohort 25,843 patients prescribed semaglutide, and (2) Non-GLP-1RA anti-diabetes medication cohort 562,006 patients prescribed non-GLP-1RA anti-diabetes medications but not semaglutide